Naldemedine tosylate - Generic Drug Details

What are the generic drug sources for naldemedine tosylate and what is the scope of patent protection?

Naldemedine tosylate is the generic ingredient in one branded drug marketed by Bdsi and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Naldemedine tosylate has seventy-five patent family members in twenty-seven countries.

One supplier is listed for this compound.

Summary for naldemedine tosylate

International Patents:	75
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
DailyMed Link:	naldemedine tosylate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for naldemedine tosylate

Constraining patent/regulatory exclusivity:

9,108,975

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for naldemedine tosylate

Drug Class	Opioid Antagonist
Mechanism of Action	Opioid Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for naldemedine tosylate

A06AH	Peripheral opioid receptor antagonists
A06A	DRUGS FOR CONSTIPATION
A06	DRUGS FOR CONSTIPATION
A	Alimentary tract and metabolism

US Patents and Regulatory Information for naldemedine tosylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bdsi	SYMPROIC	naldemedine tosylate	TABLET;ORAL	208854-001	Mar 23, 2017		RX	Yes	Yes	RE46365		Y	Y
Bdsi	SYMPROIC	naldemedine tosylate	TABLET;ORAL	208854-001	Mar 23, 2017		RX	Yes	Yes	10,952,968		Y	Y
Bdsi	SYMPROIC	naldemedine tosylate	TABLET;ORAL	208854-001	Mar 23, 2017		RX	Yes	Yes	RE46375		Y	Y
Bdsi	SYMPROIC	naldemedine tosylate	TABLET;ORAL	208854-001	Mar 23, 2017		RX	Yes	Yes	12,350,377		Y
Bdsi	SYMPROIC	naldemedine tosylate	TABLET;ORAL	208854-001	Mar 23, 2017		RX	Yes	Yes	9,108,975		Y	Y

International Patents for naldemedine tosylate

Country	Patent Number	Title	Estimated Expiration
Canada	2873961
Denmark	2851075
European Patent Office	2851075
Spain	2903149
Japan	5818219
Japan	WO2013172297
Poland	2851075

Supplementary Protection Certificates for naldemedine tosylate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1889848	2019C/533	Belgium		PRODUCT NAME: NALMEDINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT HIERVAN, IN BIJZONDER HET TOSYLAATZOUT; AUTHORISATION NUMBER AND DATE: EU/1/18/1291 20190220
1889848	CA 2019 00035	Denmark		PRODUCT NAME: NALDEMEDIN ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, SAERLIGT TOSYLAT SALTET; REG. NO/DATE: EU/1/18/1291 20190220
1889848	SPC/GB19/050	United Kingdom		PRODUCT NAME: NALDEMEDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, IN PARTICULAR THE TOSYLATE SALT; REGISTERED: UK EU/1/18/1291(FOR NI) 20190220; UK PLGB 50999/0003 20190220
1889848	19C1042	France		PRODUCT NAME: NALDEMEDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES OU SOLVATES, EN PARTICULIER LE SEL DE TOSYLATE; REGISTRATION NO/DATE: EU/1/18/1291 20190220
1889848	132019000000093	Italy		PRODUCT NAME: NALDEMEDINA O UN SUO SALE O SOLVATO FARMACEUTICAMENTE ACCETTABILE, IN PARTICOLARE IL SALE TOSILATO(RIZMOIC - NALDEMEDINA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1291, 20190220
1889848	763	Finland
1889848	300996	Netherlands		PRODUCT NAME: NALDEMEDINE DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, IN HET BIJZONDER HET TOSYLAATZOUT; REGISTRATION NO/DATE: EU/1/18/1291 20190220

Naldemedine tosylate market dynamics and financial trajectory (Symproic, movantik-class opioid-induced constipation)

Last updated: July 4, 2026

Naldemedine tosylate (Symproic) is a branded treatment for opioid-induced constipation (OIC) that has grown into a meaningful but mature revenue stream. Post-launch dynamics are driven by (1) uptake within OIC prescriber cohorts, (2) payer formulary placement and step-edit intensity, (3) ongoing generic and biosimilar-era substitution risk for branded small molecules, and (4) the pace of competitive cross-class prescribing versus peripherally acting mu-opioid receptor antagonists (PAMORAs) such as naloxegol and methylnaltrexone.

From a financial-trajectory standpoint, the core pattern is typical for established branded gastroenterology and pain-ADJ therapeutics: peak growth near initial formulary expansion followed by slower volume gains and more reliance on price and inventory management. The market’s forward path depends on how aggressively plan formularies broaden preferred PAMORA tiers and whether manufacturer-sponsored contracting can delay or narrow net-price erosion.

What is the current market size, demand profile, and revenue trajectory for naldemedine tosylate?

Demand drivers for opioid-induced constipation (OIC)

Naldemedine treats OIC in adults. Commercial demand correlates with:

• Opioid prescribing volumes across chronic pain, oncology supportive care, and post-surgical populations.
• Conversion from non-PAMORA laxatives and stimulant regimens to PAMORAs after inadequate response.
• Institutional and outpatient formulary decisions that define first-line OIC pathways.

Commercial maturity indicators that shape revenue trajectory

Key indicators typically determine the slope of revenue over time:

• Net-to-gross changes from contracting, rebates, and switching pressure.
• Share of OIC patient starts within PAMORA classes.
• Persistence and adherence patterns driven by once-daily use and tolerability profiles.

Financial trajectory: how the P&L usually evolves for mature OIC brands

As with other established OIC brands, revenue trajectory tends to shift from top-line growth to margin management:

• Volume growth slows as early prescriber cohorts saturate.
• Price increases become harder to sustain as payer coverage policies harden.
• Sales growth increasingly depends on incremental formulary wins rather than brand initiation.

Who are the competitive PAMORA and how does naldemedine tosylate compare commercially?

Competitive set

• Naloxegol (OIC PAMORA)
• Methylnaltrexone (PAMORA, includes injectable and oral formulations depending on region and product line)
• Other agents where applicable by geography and formulary structure

How competitors affect pricing and share

PAMORAs are clinically differentiated primarily through:

• Route (oral vs parenteral availability)
• Dosing convenience
• Tolerability profiles (GI adverse events)
• Payer preference lists (often tiered by formulary status)

For naldemedine, competitive impact is expected to manifest through:

• Preferential formulary placement of one PAMORA as the “preferred” option.
• Step therapy requiring failure of laxatives prior to PAMORA access.
• Switch incentives and contracting that reduce net prices for the non-preferred PAMORA.

Revenue exposure map: what typically gets hit first

• Net price: driven by payer discount pressure and 340B/IDN contract dynamics
• Prescriber share: driven by preferred formulary listing changes
• Incremental share growth: driven by OIC pathway revisions in formularies

How do payer coverage and formulary decisions drive naldemedine tosylate net revenue?

Typical payer constructs for OIC PAMORAs

Payer policies that shape outcomes include:

• Prior authorization requirements
• Quantity limits based on dosing
• Step edits requiring laxative trials
• Coverage carve-outs for subpopulations (for example, those with advanced illness, opioid regimens, or specific OIC definitions)

Contracting levers and net-price math

Market practice for branded specialty drugs suggests net revenue is affected by:

• Volume-based rebates tied to formulary access
• Spread pricing and pharmacy benefit management dynamics
• Patient assistance program impact (where applicable)

Why these dynamics matter for “financial trajectory”

In mature stages, gross sales can remain stable while net sales decline due to:

• Higher rebate rates
• Preferred-tier shifts to competitors
• Greater use of prior authorization denials and reversals

What patent and exclusivity issues affect the market dynamics for naldemedine tosylate?

How IP affects generic-entry risk

For small-molecule branded drugs like naldemedine tosylate, IP estate strength affects:

• Time to generic launch
• Settlement posture in patent litigation
• Whether generics enter “at risk” or via authorized pathways

Patent estate impact channels

• Formulation and method-of-use protection can extend exclusivity even after the base composition is challenged.
• Each Orange Book listing (drug substance and product claims) typically maps to a separate certification risk for generic applicants.
• If litigation targets key listed patents, generic timing is more likely to be synchronized with court outcomes or settlement triggers.

Exclusivity timing: what matters commercially

Market dynamics change most around:

• The first credible ANDA/Paragraph IV event
• Court or settlement outcomes
• Any changes in exclusivity status that remove barriers to automatic generic launch

What is the Orange Book status of naldemedine tosylate and what patents are listed?

When does naldemedine tosylate lose exclusivity?

What Paragraph IV challenges exist for naldemedine tosylate?

What generic entry risks exist for naldemedine tosylate?

These sections require Orange Book and litigation specifics

Producing accurate, decision-grade content on Orange Book listings, exclusivity windows, and Paragraph IV events requires the drug’s exact FDA record (application numbers, NDC-specific patent list, and listed patent grant and expiration dates) plus litigation docket outcomes. Without those record-level details, any dates or counts would be unreliable.

What patent litigation affects naldemedine tosylate and how do settlements influence launch timing?

Litigation mechanisms that alter financial outcomes

For established brands, patent litigation affects the financial trajectory through:

• Delaying generic launches
• Inducing “design-around” strategies that delay substitution at the pharmacy counter
• Post-settlement labeling or formulation carve-outs that preserve brand use for defined patient segments

What to look for in outcomes

Decision points that typically move revenue:

• Court-issued injunctions tied to specific claims
• Settlement agreements that include “180-day exclusivity” allocation for first-filers
• Stipulated entry dates by NDC strength and dosage form

What is the FDA regulatory status of naldemedine tosylate and how does it affect competition?

Regulatory status as a market limiter

Regulatory factors that shape competition include:

• Approved indications (OIC definitions)
• Label constraints and any REMS-like requirements (none expected for this class, but label constraints can impact competitive switching)
• Pediatric or expanded population exclusivity, if present in the FDA record

Label alignment affects substitution

If competitor labels lag or require different patient selection, prescribing switching can slow, supporting brand share retention.

How do manufacturing and IP barriers limit generic competition for naldemedine tosylate?

Barriers that can slow substitution

Even if patents weaken, generic substitution can be slowed by:

• Manufacturing scale-up timelines and validation
• Quality system execution and stability data generation
• Risk-managed at-launch distribution in pharmacy channels

What tends to matter commercially

• Launch readiness by dosage strength and packaging NDCs
• Pharmacy wholesaler coverage speed
• Contracted substitution policies and automatic substitution rules

How strong is the patent estate for naldemedine tosylate by claim type (composition, formulation, method-of-use)?

Claim-type impact on design-around

• Composition-of-matter claims block any identical active ingredient entry for the covered term.
• Formulation claims block specific release, salt forms, or excipient systems.
• Method-of-use claims block certain dosing regimens or patient-selection indications.

Commercial effect:

• If method-of-use is the dominant remaining layer, generic entrants may be delayed or forced into non-label use strategies that reduce substitution.

Revenue exposure and scenario analysis: how much profit is at risk from competitive PAMORA and generic entry?

Financial sensitivity framework

For mature OIC drugs, profit at risk is a function of:

• PAMORA class share and how quickly prescribers can switch within class
• Magnitude of net-price erosion after payer tier changes
• Timing and probability of generic entry once key Orange Book barriers are removed

Scenario mechanics

• Competitive switching scenario (no generic): driven by payer contracting and preferred-tier changes.
• Generic entry scenario: driven by substitution speed, rebate compression, and loss of segment access.

Key Takeaways

• Naldemedine tosylate’s financial trajectory is governed by mature branded dynamics: growth slows as formulary penetration saturates and net price becomes the primary lever.
• Market dynamics are most sensitive to payer formulary tiering among PAMORAs and the presence or absence of meaningful patent barriers.
• The largest downstream swing factor is Orange Book- and litigation-linked timing that determines when generics can enter by NDC strength and how quickly substitution occurs.
• For decision-making, track net-price trend (rebates and contracting), formulary status (preferred tier vs non-preferred), and the status of Orange Book-listed patents and any Paragraph IV events.

FAQs

1) Which payer policies most affect naldemedine tosylate coverage in OIC?

Step edits requiring laxative failure, prior authorization, and tier status for PAMORAs are the main levers.

2) How do naldemedine tosylate and naloxegol differ in commercial positioning?

They compete on payer preference, route, dosing convenience, and GI tolerability perceptions; those factors determine preferred-tier placement more than mechanistic similarity.

3) What happens to branded OIC revenue after a generic of naldemedine enters?

Revenue typically drops rapidly due to pharmacy substitution and rebate compression unless brand contracts retain preferred status or exclude defined NDCs.

4) Do formulation or method-of-use patents slow generic substitution for naldemedine?

Yes, if remaining listed claims require specific formulation characteristics or label-constrained use that generics cannot replicate for the same NDC and indication.

5) What signals indicate naldemedine tosylate is losing payer share?

Rising prior-authorization denials, tier downgrades, increased competitor utilization among initiations, and net-to-gross deterioration.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-05)
2. FDA. Drugs@FDA: naldemedine tosylate. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (accessed 2026-07-05)